^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Aybintio (bevacizumab biosimilar) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Samsung Bioepis acquires European sales license for anticancer drug'Abincio (SB8)'
Published date:
08/21/2020
Excerpt:
Samsung Bioepis (CEO: Han-Seung Ko) from the European Commission (EC) It was announced on the 21st that it has obtained the final marketing approval for'AYBINTIO ® , Avastin biosimilar, project name SB8, ingredient name bevacizumab' in Europe.
